Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

286 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
Miller RE, Leary A, Scott CL, Serra V, Lord CJ, Bowtell D, Chang DK, Garsed DW, Jonkers J, Ledermann JA, Nik-Zainal S, Ray-Coquard I, Shah SP, Matias-Guiu X, Swisher EM, Yates LR. Miller RE, et al. Among authors: scott cl. Ann Oncol. 2020 Dec;31(12):1606-1622. doi: 10.1016/j.annonc.2020.08.2102. Epub 2020 Sep 28. Ann Oncol. 2020. PMID: 33004253 Free article.
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
Lheureux S, Lai Z, Dougherty BA, Runswick S, Hodgson DR, Timms KM, Lanchbury JS, Kaye S, Gourley C, Bowtell D, Kohn EC, Scott C, Matulonis U, Panzarella T, Karakasis K, Burnier JV, Gilks CB, O'Connor MJ, Robertson JD, Ledermann J, Barrett JC, Ho TW, Oza AM. Lheureux S, et al. Clin Cancer Res. 2017 Aug 1;23(15):4086-4094. doi: 10.1158/1078-0432.CCR-16-2615. Epub 2017 Feb 21. Clin Cancer Res. 2017. PMID: 28223274 Clinical Trial.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators. Coleman RL, et al. Among authors: scott cl. Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Lancet. 2017. PMID: 28916367 Free PMC article. Clinical Trial.
Clinical research in endometrial cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
Creutzberg CL, Kim JW, Eminowicz G, Allanson E, Eberst L, Kim SI, Nout RA, Park JY, Lorusso D, Mileshkin L, Ottevanger PB, Brand A, Mezzanzanica D, Oza A, Gebski V, Pothuri B, Batley T, Gordon C, Mitra T, White H, Howitt B, Matias-Guiu X, Ray-Coquard I, Gaffney D, Small W Jr, Miller A, Concin N, Powell MA, Stuart G, Bookman MA; participants of the 2023 Gynecologic Cancer InterGroup Endometrial Cancer Consensus Conference on Clinical Research. Creutzberg CL, et al. Lancet Oncol. 2024 Sep;25(9):e420-e431. doi: 10.1016/S1470-2045(24)00192-X. Lancet Oncol. 2024. PMID: 39214113
Rucaparib for maintenance treatment of platinum-sensitive, recurrent ovarian carcinoma: Final results of the phase 3, randomized, placebo-controlled ARIEL3 trial.
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Banerjee S, García-Donas J, Swisher EM, Lebreton C, Konecny GE, McNeish IA, Scott CL, Maloney L, Goble S, Lin KK, Coleman RL. Ledermann JA, et al. Among authors: scott cl. Eur J Cancer. 2025 Jun 17;225:115584. doi: 10.1016/j.ejca.2025.115584. Online ahead of print. Eur J Cancer. 2025. PMID: 40580808
Kupffer cell programming by maternal obesity triggers fatty liver disease.
Huang H, Balzer NR, Seep L, Splichalova I, Blank-Stein N, Viola MF, Franco Taveras E, Acil K, Fink D, Petrovic F, Makdissi N, Bayar S, Mauel K, Radwaniak C, Zurkovic J, Kayvanjoo AH, Wunderling K, Jessen M, Yaghmour MH, Kenner L, Ulas T, Grein S, Schultze JL, Scott CL, Guilliams M, Liu Z, Ginhoux F, Beyer MD, Thiele C, Meissner F, Hasenauer J, Wachten D, Mass E. Huang H, et al. Among authors: scott cl. Nature. 2025 Jun 18. doi: 10.1038/s41586-025-09190-w. Online ahead of print. Nature. 2025. PMID: 40533564
Spatially restricted and ontogenically distinct hepatic macrophages are required for tissue repair.
De Ponti FF, Bujko A, Liu Z, Collins PJ, Schuermans S, Maueröder C, Amstelveen S, Thoné T, Martens L, McKendrick JG, Louwe PA, Cruz AS, Saelens W, Matchett KP, Waller KJ, Zwicker C, Bugler-Lamb A, Vanneste B, Parmentier F, Abdul Latib MB, Remmerie A, Kertesz L, Kremer A, Verbeke J, Ipsen DH, Pfister DR, Liu Z, Guilliams M, Henderson NC, Ravichandran K, Marques PE, Scott CL. De Ponti FF, et al. Among authors: scott cl. Immunity. 2025 Jun 6:S1074-7613(25)00234-1. doi: 10.1016/j.immuni.2025.05.013. Online ahead of print. Immunity. 2025. PMID: 40482642 Free article. No abstract available.
286 results